

# Mladen Vassilev Tzvetkov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7980609/publications.pdf>

Version: 2024-02-01

40  
papers

1,430  
citations

394421

19  
h-index

330143

37  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1490  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1. <i>Journal of Biological Chemistry</i> , 2022, 298, 101974.  | 3.4 | 6         |
| 2  | Cloning and Functional Characterization of Dog OCT1 and OCT2: Another Step in Exploring Species Differences in Organic Cation Transporters. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5100.   | 4.1 | 1         |
| 3  | Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport. <i>Frontiers in Pharmacology</i> , 2021, 12, 674559.   | 3.5 | 11        |
| 4  | Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 688950.                     | 3.5 | 14        |
| 5  | OCT1 Polyspecificity – Friend or Foe?. <i>Frontiers in Pharmacology</i> , 2021, 12, 698153.  | 3.5 | 5         |
| 6  | Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 628-638.   | 4.7 | 18        |
| 7  | Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 312-323.  | 2.0 | 10        |
| 8  | Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters. <i>Biochemical Pharmacology</i> , 2020, 171, 113731.  | 4.4 | 19        |
| 9  | A double-Flp-in method for stable overexpression of two genes. <i>Scientific Reports</i> , 2020, 10, 14018.  | 3.3 | 6         |
| 10 | Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans. <i>Frontiers in Genetics</i> , 2020, 11, 944.   | 2.3 | 14        |
| 11 | Differences in Metformin and Thiamine Uptake between Human and Mouse Organic Cation Transporter 1: Structural Determinants and Potential Consequences for Intrahepatic Concentrations. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1380-1392.           | 3.3 | 22        |
| 12 | OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 190-200.                                       | 4.7 | 31        |
| 13 | Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9890-9905.  | 6.4 | 24        |
| 14 | An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. <i>Chinese Journal of Natural Medicines</i> , 2019, 17, 490-497.   | 1.3 | 5         |
| 15 | Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A. <i>Frontiers in Pharmacology</i> , 2019, 10, 1297.  | 3.5 | 12        |
| 16 | Assay Conditions Influence Affinities of Rat Organic Cation Transporter 1: Analysis of Mutagenesis in the Modeled Outward-Facing Cleft by Measuring Effects of Substrates and Inhibitors on Initial Uptake. <i>Molecular Pharmacology</i> , 2018, 93, 402-415. | 2.3 | 17        |
| 17 | Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 868-878.  | 4.7 | 56        |
| 18 | The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in Caucasian patients with sepsis. <i>Scientific Reports</i> , 2018, 8, 15140.  | 3.3 | 13        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The FER rs4957796 TT genotype is associated with unfavorable 90-day survival in Caucasian patients with severe ARDS due to pneumonia. <i>Scientific Reports</i> , 2017, 7, 9887.  | 3.3 | 18        |
| 20 | Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families. <i>Biological Chemistry</i> , 2017, 398, 237-249.   | 2.5 | 28        |
| 21 | Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. <i>PLoS ONE</i> , 2017, 12, e0189521.  | 2.5 | 32        |
| 22 | OCT1 mediates hepatic uptake of sumatriptan and loss of function OCT1 polymorphisms affect sumatriptan pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 633-641.   | 4.7 | 71        |
| 23 | Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. <i>Pain</i> , 2016, 157, 2467-2475.   | 4.2 | 45        |
| 24 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. <i>Genome Medicine</i> , 2016, 8, 119. | 8.2 | 10        |
| 25 | Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. <i>Genome Medicine</i> , 2015, 7, 56.  | 8.2 | 77        |
| 26 | The CD14 rs2569190 TT Genotype Is Associated with an Improved 30-Day Survival in Patients with Sepsis: A Prospective Observational Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0127761.  | 2.5 | 16        |
| 27 | High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 1605-1619.  | 1.3 | 7         |
| 28 | Genetic Polymorphisms in Endothelin-1 as Predictors for Long-Term Survival and the Cardiac Index in Patients Undergoing On-Pump Cardiac Surgery. <i>PLoS ONE</i> , 2015, 10, e0131155.  | 2.5 | 3         |
| 29 | The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family. <i>AAPS Journal</i> , 2014, 16, 1247-1258.   | 4.4 | 82        |
| 30 | Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?. <i>Blood</i> , 2014, 123, 1427-1429.   | 1.4 | 10        |
| 31 | Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. <i>Biochemical Pharmacology</i> , 2013, 86, 666-678.                               | 4.4 | 168       |
| 32 | Lithium enhances CRTC oligomer formation and the interaction between the CREB coactivators CRTC and CBP – Implications for CREB-dependent gene transcription. <i>Cellular Signalling</i> , 2013, 25, 113-125.                                   | 3.6 | 15        |
| 33 | Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. <i>Pharmacogenomics Journal</i> , 2012, 12, 22-29.   | 2.0 | 128       |
| 34 | The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. <i>Biochemical Pharmacology</i> , 2012, 83, 1427-1434.  | 4.4 | 56        |
| 35 | Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. <i>Pharmacogenomics</i> , 2011, 12, 1417-1427.  | 1.3 | 48        |
| 36 | Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 143-150.                            | 4.7 | 126       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. <i>Pharmacogenomics</i> , 2010, 11, 449-457.                      | 1.3 | 25        |
| 38 | Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. <i>Biochemical Pharmacology</i> , 2009, 78, 45-53. | 4.4 | 44        |
| 39 | Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 495-506.             | 1.5 | 68        |
| 40 | Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. <i>Gene</i> , 2007, 386, 52-62.   | 2.2 | 65        |